PARDS Prone Position and HFOV: PROSpect Trial Results

The international PROSpect trial tested two rescue-style strategies in children with early moderate-to-severe pediatric acute respiratory distress syndrome (PARDS): prone positioning and high-frequency oscillatory ventilation (HFOV). Neither strategy increased the number of ventilator-free days. The authors do not recommend routine use of either as a first-line approach in this population.

What happened

PROSpect used a 2×2 factorial design. This structure lets investigators test two interventions in the same cohort: prone positioning versus supine, and HFOV versus conventional ventilation. Participants were children with early PARDS of moderate or severe degree.

The main finding was neutral. Neither prone positioning nor HFOV increased ventilator-free days, the outcome that counts time alive and off the ventilator. On this basis, the authors advise against using either intervention routinely as first-line therapy in this group.

The summary I worked from does not include sample size, effect estimates, confidence intervals, secondary outcomes, or safety data. Check the full paper in The Lancet for those details before citing numbers anywhere.

Why it matters

Pediatric intensivists have long borrowed from adult ARDS research. Adult data for prone positioning are fairly strong in severe disease, while adult HFOV data are unfavorable. Children are not small adults, though. Their chest wall compliance, airway size, and lung development differ, and PARDS has its own definition and its own causes, such as viral bronchiolitis and pneumonia. A large pediatric trial that tests these strategies directly is therefore valuable.

For learners, PROSpect is also a good example of how a plausible physiologic rationale can fail to produce a better outcome. That lesson comes up often in critical appraisal questions.

What to know for the USMLE — high-yield points

• ARDS pathophysiology: Injury to the alveolar-capillary barrier causes diffuse alveolar damage, with neutrophil-rich inflammation, hyaline membranes, and increased permeability. The result is noncardiogenic pulmonary edema, with surfactant dysfunction, atelectasis, decreased compliance, and intrapulmonary shunt. Hypoxemia responds poorly to supplemental oxygen because of the shunt.
• Diagnosis: The adult Berlin definition requires acute onset within 1 week of a known insult, bilateral opacities, and respiratory failure not fully explained by heart failure or fluid overload. It also requires impaired oxygenation (PaO₂/FiO₂) on PEEP of at least 5 cmH₂O. Pediatric criteria (PALICC) rely on the oxygenation index rather than PaO₂/FiO₂ alone. Expect the exam to test the adult definition more often.
• Pulmonary capillary wedge pressure: It is classically normal or low in ARDS and elevated in cardiogenic edema.
• Cornerstone of management: Lung-protective ventilation means low tidal volumes (about 6 mL/kg predicted body weight in adults), plateau pressure kept below 30 cmH₂O, and adequate PEEP. Permissive hypercapnia is accepted. This approach reduces ventilator-induced lung injury (volutrauma, barotrauma, atelectrauma, biotrauma).
• Prone positioning: It makes the distribution of ventilation and perfusion more uniform, recruits dorsal lung regions, and improves V/Q matching. The classic adult evidence is the PROSEVA trial, in which long prone sessions reduced mortality in severe ARDS. PROSpect did not show a gain in ventilator-free days in children.
• HFOV: It delivers very small tidal volumes at high frequency around a constant high mean airway pressure. In theory this is lung-protective. The adult OSCILLATE trial found harm, and OSCAR found no benefit. Risks include reduced venous return and hypotension from high mean airway pressure, the need for deep sedation, and barotrauma.
• Other adult adjuncts to recognize: Neuromuscular blockade in early severe ARDS, conservative fluid strategy once shock has resolved, and ECMO as a rescue option. Routine corticosteroids and inhaled nitric oxide are not standard therapies for every patient.
• Critical appraisal terms: Ventilator-free days is a composite outcome. It combines mortality (patients who die are usually assigned zero days) with duration of ventilation. A factorial design tests two interventions at once and can also assess interaction between them. A neutral trial does not prove the interventions are useless. It shows no demonstrated benefit on the primary outcome, in that population and under those protocols.

Limitations

• Limited source detail. My summary lacks the numbers and trial specifics. I cannot comment on effect sizes, precision, adverse events, or subgroup findings.
• Population-specific result. The finding applies to children with early moderate-to-severe PARDS. It should not be extended to adults, to milder disease, or to late rescue use. The authors' recommendation is about routine first-line use, not about every possible scenario.
• Surrogate-like outcome. Ventilator-free days are practical and widely used, but they are not the same as long-term survival or functional recovery. A neutral result on this outcome does not exclude differences in other outcomes.
• Protocol dependence. Results reflect how prone positioning and HFOV were applied in the trial, including timing, duration, and settings. Practice outside a trial can differ.
• Exam caution. Board questions favor established principles. Lung-protective ventilation remains the baseline strategy, and a single new study does not change the standard teaching.

FAQ

Did the PROSpect trial find prone positioning harmful in pediatric ARDS?

The summary says only that prone positioning did not increase ventilator-free days. It does not report harm. Safety outcomes would be in the full publication.

Does this change adult ARDS management for Step 1 or Step 2 CK?

No. PROSpect studied children. For exams, adult ARDS teaching still emphasizes low tidal volume ventilation, appropriate PEEP, and prone positioning in severe cases, per the adult evidence. HFOV is not recommended as routine adult therapy.

What are ventilator-free days?

It is a composite outcome that reflects both survival and time off mechanical ventilation within a fixed window, often 28 days. Because deaths are typically counted as zero ventilator-free days, the measure can be affected by mortality as well as ventilator duration. The exact definition used in PROSpect is in the full paper.

Key takeaways

• In PROSpect, a 2×2 factorial trial in children with early moderate-to-severe PARDS, neither prone positioning nor HFOV increased ventilator-free days, and the authors do not advise routine first-line use.
• For USMLE, keep the core ARDS framework: diffuse alveolar damage, noncardiogenic edema, shunt physiology, and lung-protective ventilation with adequate PEEP as the foundation of care.
• Use this trial to practice critical appraisal: understand factorial designs, composite outcomes like ventilator-free days, and the difference between a biologically plausible therapy and one that improves outcomes.